Table 4.
Prevalence ratio of HPV16, 31, 33, 45, 52 and 58 seronegativity comparing HPV18 seronegative to HPV18 seropositive among quadrivalent vaccine recipients
| Prevalence ratio (95% confidence intervals) of seronegativity comparing the HPV18 seronegative to the HPV18 seropositive women | |
|---|---|
| HPV type | Neutralizing HPV18 antibody seronegative vs. seropositive |
| HPV16 | 70.0 (9.32–526) |
| HPV45 | 1.16 (1.07–1.26) |
| HPV31 | 1.60 (1.31–1.97) |
| HPV33 | 1.35 (1.15–1.60) |
| HPV52 | 1.86 (1.40–2.47) |
| HPV58 | 1.34 (1.15–1.57) |
| Alpha 9 Clade seronegative to any (16/31/33/52/58) | 1.24 (1.17–1.31) |
| Alpha 9 Clade seronegative to all (16/31/33/52/58) | ne |
HPV seronegativity is measured via type specific neutralizing or cross-neutralizing antibody seronegativity. ne not possible to estimate.